RxDoctor Payments Data

Paul Kalogerou, MD

Internal Medicine · van Wert, OHNPI 1376535914

Payments from drug & device makers

$4,985in general payments, 2019–2025

Across 352 payments — averaging $14.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$731
  • Novo Nordisk$608
  • Lilly USA, LLC$387
  • Vanda Pharmaceuticals Inc.$246
  • Pfizer$172
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,92299%
  • Education$331%
  • Other$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,985 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$57,456
Medicare patients
259
Services billed
641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban576$261,181
JardianceEmpagliflozin222$174,000
Invega SustennaPaliperidone Palmitate59$173,358
TrulicityDulaglutide97$142,596
AustedoDeutetrabenazine23$115,149
FanaptIloperidone45$109,392
Dupixent SyringeDupilumab26$102,112
OzempicSemaglutide54$83,468
JanuviaSitagliptin Phosphate122$74,834
Bydureon BciseExenatide Microspheres82$68,600
LinzessLinaclotide109$66,078
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$65,887
Risperdal ConstaRisperidone Microspheres30$60,958
VraylarCariprazine Hcl41$42,665
XareltoRivaroxaban124$42,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta, Xarelto, Invokana$11$291,391236 claims
PfizerEliquis, Abrysvo$172$289,470666 claims
Boehringer IngelheimJardiance, Tradjenta$147$188,884266 claims
AbbVieLinzess, Vraylar, Viberzi, Creon$1,039$148,161181 claims
Lilly USA, LLCTrulicity$387$142,59697 claims
Teva Pharmaceuticals USA, Inc.Austedo$69$115,14923 claims
Vanda Pharmaceuticals Inc.Fanapt$246$109,39245 claims
Novo NordiskOzempic$608$83,46854 claims
GSKTrelegy Ellipta, Breo Ellipta$54$80,884131 claims
MerckJanuvia$58$74,834122 claims
AstraZenecaFarxiga, Breztri Aerosphere$731$48,02670 claims
NovartisEntresto$13$41,22855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in van Wert

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →